ATE500266T1 - Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine - Google Patents

Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine

Info

Publication number
ATE500266T1
ATE500266T1 AT04735139T AT04735139T ATE500266T1 AT E500266 T1 ATE500266 T1 AT E500266T1 AT 04735139 T AT04735139 T AT 04735139T AT 04735139 T AT04735139 T AT 04735139T AT E500266 T1 ATE500266 T1 AT E500266T1
Authority
AT
Austria
Prior art keywords
protein variant
biological response
effectiveness
improving
host cell
Prior art date
Application number
AT04735139T
Other languages
English (en)
Inventor
Yong-Hoon Chung
Hak-Sup Lee
Ki-Wan Yi
Youn-Hwa Heo
Jae-Youn Kim
Original Assignee
Medexgen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medexgen Co Ltd filed Critical Medexgen Co Ltd
Application granted granted Critical
Publication of ATE500266T1 publication Critical patent/ATE500266T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT04735139T 2003-07-26 2004-05-27 Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine ATE500266T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030051846A KR100632985B1 (ko) 2003-07-26 2003-07-26 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
PCT/KR2004/001246 WO2005010043A1 (en) 2003-07-26 2004-05-27 A method of improving efficacy of biological response-modifying proteins and the exemplary muteins

Publications (1)

Publication Number Publication Date
ATE500266T1 true ATE500266T1 (de) 2011-03-15

Family

ID=36284112

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04735139T ATE500266T1 (de) 2003-07-26 2004-05-27 Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine

Country Status (14)

Country Link
US (3) US7569361B2 (de)
EP (1) EP1668030B1 (de)
JP (1) JP4747238B2 (de)
KR (1) KR100632985B1 (de)
CN (2) CN102286090A (de)
AT (1) ATE500266T1 (de)
AU (1) AU2004259314B2 (de)
BR (1) BRPI0412607A (de)
CA (1) CA2528458A1 (de)
DE (1) DE602004031642D1 (de)
ES (1) ES2362453T3 (de)
RU (1) RU2432360C2 (de)
WO (1) WO2005010043A1 (de)
ZA (1) ZA200600502B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP1877434A2 (de) * 2005-05-04 2008-01-16 Nautilus Biotech Modifizierte interferon-gamma-polypeptide und verfahren zur anwendung modifizierter interferon-gamma-polypeptide
EP2120998B1 (de) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modifizierte erythropoetin-polypeptide und ihre verwendungen zur behandlung
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
EP2009103A1 (de) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophische Peptide
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
KR101510743B1 (ko) * 2013-07-23 2015-04-10 (주)케어젠 파골 세포 분화 억제용 펩타이드 및 이의 용도
US10052343B1 (en) * 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
KR101947342B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Gm-csf 반감기를 증가시키는 방법
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
PH12020550661A1 (en) 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
EP4090674A4 (de) 2020-01-14 2024-01-24 Synthekine, Inc. Vorgespannte il2-muteins-verfahren und -zusammensetzungen
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
AU2023378481A1 (en) * 2022-11-10 2025-06-19 Kanglitai Biomedical (Qingdao) Co., Ltd. Site-specific pegylated heteromeric protein or polypeptide, and preparation method therefor and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IL192290A0 (en) * 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
WO1999057147A1 (fr) * 1998-04-30 1999-11-11 Kirin Brewery Company, Limited Mutants de la thrombopoietine humaine
WO2003104263A2 (en) * 2002-05-01 2003-12-18 Genencor International, Inc. Cytokines and cytokine receptors with reduced immunogenicity

Also Published As

Publication number Publication date
EP1668030B1 (de) 2011-03-02
CN101384620A (zh) 2009-03-11
CN101384620B (zh) 2011-08-17
US20100041586A1 (en) 2010-02-18
EP1668030A1 (de) 2006-06-14
ES2362453T3 (es) 2011-07-05
AU2004259314B2 (en) 2006-12-07
JP2007524403A (ja) 2007-08-30
US7569361B2 (en) 2009-08-04
BRPI0412607A (pt) 2007-07-03
RU2006102846A (ru) 2007-09-10
DE602004031642D1 (de) 2011-04-14
WO2005010043A1 (en) 2005-02-03
EP1668030A4 (de) 2006-06-14
KR20050013024A (ko) 2005-02-02
AU2004259314A1 (en) 2005-02-03
US20130089513A1 (en) 2013-04-11
KR100632985B1 (ko) 2006-10-11
CN102286090A (zh) 2011-12-21
JP4747238B2 (ja) 2011-08-17
ZA200600502B (en) 2007-02-28
US20060008872A1 (en) 2006-01-12
RU2432360C2 (ru) 2011-10-27
CA2528458A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
DE602004031642D1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
WO2006014349A3 (en) Method of producing fully carbamylated erythropoietin
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MXPA05014215A (es) Mapeo de genoma de elementos funcionales de adn y proteinas celulares.
EA021222B8 (ru) Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
EP2540309A3 (de) Gewebeschützende Peptide und ihre Verwendung
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
PT973794E (pt) Receptores de netrina
Białkowska et al. Extremophilic proteases as novel and efficient tools in short peptide synthesis
Martina et al. Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
DE69826493D1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
ATE532863T1 (de) Verfahren zur anzucht von myokardzellen
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
DE69826717D1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
WO1997014966B1 (en) Method of activating a novel ligand regulatory pathway
DE60032161D1 (de) P-glycoproteine und ihre verwendungen
Antonyan et al. Proline-rich cytokine from neurosecretory granules: A new natural substrate for dipeptidyl peptidase IV

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties